J&J reports Tremfya demonstrates MRI-confirmed improvements in spinal pain and stiffness
JNJ•Johnson & Johnson said Tremfya showed statistically significant improvement in BASDAI score versus placebo in a Phase 4 study and reduced MRI-assessed inflammation by more than 2 times versus placebo at week 24. The safety profile was consistent, with no new safety signals identified.
1. Phase 4 findings
Johnson & Johnson said Tremfya demonstrated MRI-confirmed improvements in spinal pain and stiffness in the STAR study. The drug showed statistically significant improvement in BASDAI score versus placebo and more than 2 times greater reduction in MRI-assessed inflammation at week 24; its safety profile was consistent, with no new safety signals identified.




